EVALUATION  OF  IMMUNOLOGICAL  SHIFTS  IN  ADULTS  AFTER  IMMUNIZATION  AGAINST INFLUENZA  WITH  A  SUBUNIT-BASED,  ABSORBED  MONOVALENT  VACCINE  STRAIN  A/CALIFORNIA/7/2009/(H1N1)

M. P. Kostinov; O. A. Terkacheva; S. N. Girova; N. E. Jastrebova; A. P. Cherdantsev

doi:10.15789/1563-0625-2011-1-35-40

EVALUATION OF IMMUNOLOGICAL SHIFTS IN ADULTS AFTER IMMUNIZATION AGAINST INFLUENZA WITH A SUBUNIT-BASED, ABSORBED MONOVALENT VACCINE STRAIN A/CALIFORNIA/7/2009/(H1N1)

M. P. Kostinov, O. A. Terkacheva, S. N. Girova, N. E. Jastrebova, A. P. Cherdantsev

https://doi.org/10.15789/1563-0625-2011-1-35-40

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Abstract. Seventy healthy volunteers were immunized with influenza subunit vaccine strain A/California/7/2009 / (H1N1), in order to test possible changes in auto-reactivity. It was shown that the vaccine is safe and immunogenic. In addition, it was revealed that a double injection of the vaccine was not accompanied by development of autoantibody response, both to tissue antigens (specifically, to lung tissue, or basic myelin protein), and to those against non-tissue antigens (native or denatured DNA). In some cases, application of the vaccine was accompanied by a significant reduction in levels of autoantibodies. It was also noted that injection of the vaccine is accompanied by a reduction in total IgE levels in patients with increased baseline IgE levels. Following double injection of the vaccine at a single dose of 0.5 ml, the frequencies of seroconversion was 71.4%, seroprotection levels were achieved in 59,2%, whereas seroconversion factor proved to be 4.92, thus meeting the CPMP criteria. (Med. Immunol., 2011, vol. 13, N 1, pp 35-40)

Keywords

influenza vaccine , autoantibodies , safety , immunogenicity , autoreactivity

About the Authors

M. P. Kostinov

Учреждение Российской академии медицинских наук Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН, Москва
Russian Federation

O. A. Terkacheva

S. N. Girova

N. E. Jastrebova

A. P. Cherdantsev

ИМЭиФКУл ГУ, г. Ульяновск
Russian Federation

References

1. Безопасность пандемических вакцин. Пандемический грипп (H1N1). – 2009: Всемирная организация здравоохранения 2009 г. / Краткое сообщение № 21.

2. Медуницин Н.В. Вакцинология. Издание третье, перераб. и доп. –М.: «Триада-Х», 2010. – 512 с.

3. Некрасов А.В., Пучкова Н.Г., Харит С.М., Беляева Т.Б.,Лиознов Д.А., Ельшина Г.А., Гор-бунов Н.И., Лонская Н.И. Вакцина Грипол Нео: результаты клинических исследований безопаст-ности и реактогенности (фаза 11) // Эпидем. вакцинопроф. – 2009. –№ 5. – С. 48-49.

4. Ястребова Н.Е., Ванеева Н.П., Романова Р.Ю. Антитела к органоспецефическим и органонеспецифическим антигенам в сыворотках крови людей, больных бронхо-легочными заболеваниями // Журн. микробиол. – 1996. – № 6. – С. 67-68.

5. Basta N.E., Chao D.L., Halloran M.E., Matrajt L., Longini I.M. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States // Am J. Epidemiol. – 2009. – Vol. 6. – P. 679-686.

6. Burby, Moran, Makowska A., Kabongo M.L., Steigbigel R., Belshe R.B., Kitt E.R., Chu A.H., Moss R.B. Immune responses to myelin proteins in Guillain–Barrй syndrome // J. Neurol Neurosurg Psychiatry. – 2008. – Vol. 79. – Р. 664-671.

7. DeStefano F., Verstraeten T., Jackson L.A., Catherine A. Okoro, Benson P., Black S.B., Shinefield H.R., Mullooly J.P., Likosky W., Robert T., Chen M. Vaccinations and risk of central nervous system demyelinating diseases in adults // J. ArchofNeurol. – 2003. – Vol. 60. – P. 504-509.

8. Greene S.K., Kulldorff M., Lewis E.M, Li R., Yin R., Weintraub E.S., Fireman B.H., Lieu T.A., Nordin J.D., Glanz J.M., Baxter R., Jacobsen S.J., Broder K.R., Lee G.M. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project // JAMA. – 2006. – Vol. 16. – P. 1990-1997.

9. Gazit V., Tasher D., Hanukoglu A., Landau Z., Ben-ehuda Y., Somekh E., Dalal I. Atopy in children and adolescents with insulin-dependent diabetes mellitus // Isr. Med Assoc J. – 2008. – Vol. 10. – P. 858-861.

10. Haber P., Sejvar J., Mikaeloff Y., DeStefano F. Vaccines and Guillain–Barrй syndrome // Drug Saf. – 2009. – Vol. 4. – P. 309-323.

11. Influenza Vaccine and Guillain–Barrй Syndrome: CDC, Food and Drug Administration / Vaccine Adverese Event Reporting System (VAERS).

12. Iskander J., Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience // Expert Rev. Vaccines. – 2008. – Vol. 1. – P. 75-82.

13. Kramarz P., DeStefano F., Gargiullo P.M., Braun M.M., Ball R. Inactivated Influenza Vaccines: Reports to the Vaccine Adverse Event Reporting System (VAERS). – United States, 1991-2001 // Pharmacoepidemiology and Drug Safety. – 2004.

14. Liang X.F., Wang H.Q., Wang J.Z. Fang H.H., Wu J., Zhu F.C., Li R.C., Xia S.L., Zhao Y.L., Li F.J., Yan S.H., Yin W.D., An K., Feng D.J., Cui X.L., Qi F.C., Ju C.J., Zhang Y.H., Guo Z.J., Chen P.Y., Chen Z., Yan K.M., Wang Y. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial // Lancet. – 2010. – Vol. 375. – P. 56-66.

15. Lindelйf B., Granath F., Tengvall-Linder M., Lindelцf H., Ekbom A. Allergy and autoimmune disease: a registry-based study // Clin Exp. Allergy. – 2009. – Vol. 3. – P. 110-115.

16. Muetsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Inactivated intranasal influenza vaccine and the risk of Bell’s Palsy in Switzerland // New Engl. J. Med. – 2004. – Vol. 350. – P. 896-903.

17. Nachamkin I., Shadomy S.V., Moran A.P., Cox N., Fitzgerald C., Ung H., Corcoran A.T., Iskander J.K., Schonberger L.B., Chen R.T. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain–Barrй syndrome // J. Infect. Dis. – 2008. – Vol. 2. – P. 226-233.

18. Nicoll A., Ammon A., Amato A., Liff J., Klein M., Mullooly J., Black S., Shinefield H., Ward J., Marcy M. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe // Public Health. – 2010. – Vol. 1. – P. 14-23.

19. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain–Barrй syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database // Am J. Epidemiol. – 2009. – Vol. 3. – P. 382-388.

20. Update on Influenza A (H1N1) 2009 Monovalent Vaccines: Centers for Disease Control and Prevention (CDC) // Morbidity & Mortality Weekly Report. – 2009. – Vol. 39. – P. 1100-1101.

21. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine fo the 2009-10 influenza season: a multicentre, randomised controlled trial // Lancet. – 2010. –Vol. 375. – P. 449-455.

Review

For citations:

Kostinov M.P., Terkacheva O.A., Girova S.N., Jastrebova N.E., Cherdantsev A.P. EVALUATION OF IMMUNOLOGICAL SHIFTS IN ADULTS AFTER IMMUNIZATION AGAINST INFLUENZA WITH A SUBUNIT-BASED, ABSORBED MONOVALENT VACCINE STRAIN A/CALIFORNIA/7/2009/(H1N1). Medical Immunology (Russia). 2011;13(1):35-40. (In Russ.) https://doi.org/10.15789/1563-0625-2011-1-35-40

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical Immunology (Russia)